将儿童伤害研究证据纳入立法和实践:需要多长时间?
Rebecca Mitchell1, Shalini Wijekulasuriya1, Gifty Varghese1
1Centre for Healthcare Resilience and Implementation Science, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia.
Public health
|October 29, 2025
概括
儿童伤害预防研究在澳大利亚平均需要19年才能成为法律. 这种长期的知识转化差距凸显了需要更快地实施基于证据的干预措施来保护儿童的必要性.
科学领域:
- 公共卫生 公共卫生
- 卫生政策 卫生政策
- 伤害预防 研究 研究 研究 预防伤害
背景情况:
- 在澳大利亚,童年受伤造成的公共卫生负担很大.
- 将科学证据转化为有效的公共政策和实践对于预防伤害至关重要.
研究的目的:
- 确定澳大利亚儿童伤害预防干预措施的开创性研究出版和立法颁布之间的时间间隔.
- 确定知识翻译速度较慢的特定领域.
主要方法:
- 使用案例研究和全面的文献和文档分析.
- 检查了九个关键的伤害预防措施,用于常见的童年伤害,如烧伤,溺水,中毒和道路创伤.
- 分析了与伤害预防有关的开创性研究和澳大利亚立法.
主要成果:
- 研究报告发布和研究干预措施的立法颁布之间平均花费了19年.
- 道路创伤干预的滞后时间最短 (10年),而与产品相关的安全措施平均为24年.
- 与建筑相关的干预措施,如游泳池围,根据新建或现有结构显示了18-23年的滞后.
结论:
- 在伤害预防研究与其在澳大利亚政策和实践中的实施之间存在重大知识转化差距.
- 迫切需要加快将研究成果转化为可行的战略,以减少儿童受伤.
- 根据科学证据及时制定政策对于加强儿童安全工作至关重要.
相关概念视频
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Standards of Care I
1.0K
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
1.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
189
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
189
Hazard Ratio
558
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
558
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
397
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
397


